Form 4: Revolution Medicines Exec Sells Shares for Tax Obligations

Revolution Medicines' President of R&D, Stephen Michael Kelsey, sold 4,302 shares of common stock to cover tax withholding on RSU vesting.

Summary

• Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, Inc., reported a sale of common stock.
• The transaction involved 4,302 shares of common stock.
• The shares were sold at a price of $99.4804 per share.
• The sale was executed on March 17, 2026.
• This transaction was made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023.
• The purpose of the sale was to satisfy the reporting person's tax withholding obligation upon the vesting of restricted stock units (RSUs) after July 15, 2023.
• Following the transaction, Stephen Michael Kelsey beneficially owns 295,398 shares of common stock, which includes 84,250 RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, typical for executive compensation and tax planning, with no direct implications for company performance or future prospects.

Future Outlook

This filing reports a past transaction and does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that routine insider sales, particularly those pre-arranged under Rule 10b5-1 plans for tax purposes, are common and generally do not signal a change in management's outlook on the company's prospects. Such transactions are typically part of an executive's compensation and financial planning strategy.

Stakeholder Impact

• Minimal direct impact on shareholders as this is a routine, pre-planned tax-related sale by an executive, not indicative of a change in company fundamentals or management confidence.

Key Dates

Recommendation

The transaction is a routine, pre-planned sale by an executive to cover tax obligations related to RSU vesting, executed under a Rule 10b5-1 plan. Such sales are common and typically do not reflect a change in the executive's confidence in the company's long-term prospects. Therefore, it provides no new fundamental information to warrant a change in investment recommendation.

Keywords

Revolution Medicines, RVMD, Stephen Michael Kelsey, insider trading, stock sale, RSU, 10b5-1, tax withholding